Cronos Group Inc.

$CRON
Medicinal Chemicals and Botanical Products
Health Care

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

IPO Year:

Exchange: NASDAQ

Website: thecronosgroup.com

Recent Analyst Ratings for Cronos Group Inc.

DatePrice TargetRatingAnalyst
11/2/2022$3.00Mkt Perform
Bernstein
7/28/2022Hold → Buy
Canaccord Genuity
5/11/2022Neutral → Sector Outperform
CIBC
3/22/2022Underweight → Equal Weight
Barclays
3/7/2022$4.00 → $3.00Neutral
Piper Sandler
2/22/2022$7.00 → $4.25Sell
Canaccord Genuity
2/22/2022$7.00 → $4.00Neutral
Piper Sandler
1/27/2022$5.54 → $3.24Underperform → Hold
Jefferies
11/18/2021$5.00Underperform
BofA Securities
11/18/2021$5.50Underweight
Barclays
See more ratings

Cronos Group Inc. Press Releases

Fastest customizable press release news feed in the world

See more
  • Cronos Appoints Anna Shlimak as Chief Financial Officer

    TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Speak at the 37th Annual Roth Conference

    TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the 37th Annual Roth Conference on Monday, March 17, 2025, at 1:00 PM PT. A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consum

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025

    TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

    TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Spinach® Is the Number One Cannabis Brand in Canada

    TORONTO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabinoid company, is proud to announce that its award-winning brand Spinach® has risen to the best-selling cannabis brand in the Canadian market.1 Spinach's market share outperformance represents Cronos' relentless commitment to quality, innovation, and bringing differentiated products to the competitive Canadian adult-use market. Since launching in November 2018, Spinach has quickly become the preferred choice among new and seasoned adult consumers alike. The success of Spinach is bolstered by its best-selling and breakthrough portfolio of products, including ranking

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Lord Jones® Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across Canada

    TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") is expanding its portfolio for its Lord Jones® brand with new innovations to bolster its lineup of premium cannabis products in the Canadian market. The additions include new cultivars for the Lord Jones® Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes, which are now available across Canada. Since the brand's launch in Canada in November 2023, Ice Water Hash Fusions Pre-Rolls have become the best-selling hash-infused pre-rolls in the country1. Curated with flower and terpene-rich ice water hash and fitted with a branded ceramic tip designed to cool the smoke, the

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2024 Second Quarter Earnings Conference Call on August 8, 2024

    TORONTO, July 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 second quarter earnings conference call on Thursday, August 8, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

    TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Reconvene Virtual 2024 Annual Meeting of Shareholders

    TORONTO, July 05, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announced today that it will reconvene its 2024 Annual Meeting of Shareholders on Friday, July 19, 2024, at 11:00 a.m. ET. Cronos will be conducting the reconvened meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the reconvened 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote. The record date for the Annual Meeting continues to be April 25, 2024. The Company's proxy statement and proxy supplement desc

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Brand Spinach® Celebrates Summer with New Launches

    TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc.'s (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") Spinach® brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach® edibles and a premier milled flower product. The new SOURZ by Spinach® Fully Blasted gummies offer the same great-tasting SOURZ by Spinach® flavors, now with 10 mg of THC per piece. The SOURZ by Spinach® Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach® "S" shape. These gummies have a perfect blend of sour and sweet

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

Cronos Group Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

Cronos Group Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Cronos Group Inc. SEC Filings

See more

Cronos Group Inc. Leadership Updates

Live Leadership Updates

See more
  • Cronos Appoints Anna Shlimak as Chief Financial Officer

    TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders

    TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders

    TORONTO, June 21, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held yesterday, June 20, 2024 (the "Meeting"), shareholders holding a total of 274,097,252 common shares of the Company voted in person or by proxy, representing 71.75% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 26, 2024 was elected as a director of the Company, with each director receiving in excess of 93.4% of the votes cast in favor of his or her election. The detailed results of the vote for the electio

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. Announces Results of 2023 Annual Meeting of Shareholders

    TORONTO, June 23, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held yesterday, June 22, 2023 (the "Meeting"), shareholders holding a total of 247,410,987 common shares of the Company voted in person or by proxy, representing 64.96% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's proxy statement dated April 28, 2023 (the "Proxy Statement") was elected as a director of the Company, with each director receiving in excess of 94.8% of the votes cast in favor of his or her election. The detailed results of the vote fo

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Appoints James Holm as Chief Financial Officer

    TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of James Holm as Chief Financial Officer, effective immediately. Mr. Holm succeeds Bob Madore, who is leaving the Company. Mr. Holm brings to Cronos nearly two decades of finance and accounting experience at leading companies across industries. He most recently served as the Global Vice President of Finance Transformation at Vertiv, a global provider of critical digital infrastructure and continuity solutions, where he led the company's centralization, standardization and optimization to a Global Shared

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • CBD Oil Market to Hit Nearly US$137 Billion by 2029

    FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

    $CGC
    $CRON
    $FLGC
    $OGI
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Cronos Group Inc. Announces Results of 2022 Annual Meeting of Shareholders

    TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held on June 23, 2022 (the "Meeting") shareholders voting in person or by proxy held in total 265,763,587 common shares of the Company, representing 70.76% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's proxy statement dated April 29, 2022 (the "Proxy Statement") was elected as a director of the Company, with each director receiving in excess of 91.6% of the votes cast in favor of his or her election. The detailed results of the vote for the electio

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. Announces Results of 2021 Annual Meeting of Shareholders

    TORONTO, June 25, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos Group" or the "Company") announces that at its Annual Meeting of Shareholders held earlier today (the "Meeting") there were 430 shareholders voting in person or by proxy holding in total 280,023,803 common shares of the Company, representing 75.35% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's proxy statement dated April 27, 2021 (the "Proxy Statement") was elected as a director of the Company, with each director receiving in excess of 94.38% of the votes cast in favor of his or her election. The detailed results of th

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • urban-gro, Inc. Announces Inclusion in Russell 2000® Index and Appoints Seasoned Executives to Board of Directors

    - Company added to the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes - Appointment of Anita Britt and David Hsu to Board of Directors bolsters international operational and financial expertise with a successful track record of driving growth and profitability LAFAYETTE, Colo., June 14, 2021 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), a leading global horticulture company that engineers and designs commercial Controlled Environment Agriculture ("CEA") facilities and integrates complex environmental equipment systems, today announced that it has been selected to be added to the Russell 2000® Index effective J

    $CRON
    $UGRO
    Medicinal Chemicals and Botanical Products
    Health Care
    Industrial Specialties
    Consumer Discretionary
  • Altria Participates in the Morgan Stanley Global Consumer and Retail Conference; Reaffirms 2020 Full-Year Earnings Guidance

    RICHMOND, Va.--(BUSINESS WIRE)--Altria Group, Inc. (Altria) (NYSE: MO) is participating today in the Morgan Stanley Global Consumer and Retail Conference. Billy Gifford, Altria’s Chief Executive Officer, and Sal Mancuso, Chief Financial Officer, will host virtual meetings with investors to discuss Altria's business fundamentals. 2020 Full-Year Guidance Altria reaffirms its guidance for 2020 full-year adjusted diluted earnings per share (EPS) to be in a range of $4.30 to $4.38. This range represents a growth rate of 2% to 4% from an adjusted diluted EPS base of $4.21 in 2019, as shown in Schedule 1, and excludes the special items recorded in the first nine months of 2020, also sh

    $BUD
    $MS
    $MO
    $CRON
    Beverages (Production/Distribution)
    Consumer Staples
    Investment Bankers/Brokers/Service
    Finance

Cronos Group Inc. Financials

Live finance-specific insights

See more
  • Cronos Group Inc. to Hold 2024 Fourth Quarter and Full-Year Earnings Conference Call on February 27, 2025

    TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024

    TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2024 Second Quarter Earnings Conference Call on August 8, 2024

    TORONTO, July 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 second quarter earnings conference call on Thursday, August 8, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2024 First Quarter Earnings Conference Call on May 9, 2024

    TORONTO, April 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on t

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024

    TORONTO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2023 fourth quarter and full-year earnings conference call on Thursday, February 29, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2023 Third Quarter Earnings Conference Call on November 8, 2023

    TORONTO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2023 third quarter earnings conference call on Wednesday, November 8, 2023 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for repl

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2023 Second Quarter Earnings Conference Call on August 8, 2023

    TORONTO, July 20, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2023 second quarter earnings conference call on Tuesday, August 8, 2023 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2023 First Quarter Earnings Conference Call on May 9, 2023

    TORONTO, April 25, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2023 first quarter earnings conference call on Tuesday, May 9, 2023 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on th

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2022 Fourth Quarter and Full-Year Earnings Conference Call on February 28, 2023

    TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2022 fourth quarter and full-year earnings conference call on Tuesday, February 28, 2023 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archi

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
  • Cronos Group Inc. to Hold 2022 Third Quarter Earnings Conference Call on November 7, 2022

    TORONTO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2022 third quarter earnings conference call on Monday, November 7, 2022 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on

    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

Cronos Group Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more